Close Menu

Supreme Court

Athena and its supporters have asked the Supreme Court to clarify patent eligibility, but Mayo recently countered that this is a job for legislators.

Bit of Uncertainty

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

The Thermo Fisher subsidiary is not liable to Promega in the US for selling infringing forensic DNA kits in Europe, containing US-manufactured Taq polymerase.

The case is being framed as either upholding a strong patent regime or dealing a blow to US-based manufacturing as part of the global supply chain.

Arti Rai and Colleen Chien are studying whether the Supreme Court's decisions in Mayo v Prometheus and Bilski v Kappos have had a negative impact on diagnostics innovation.

NEW YORK (GenomeWeb) – While industry observers might disagree about whether GeneDx's decision to apply for inter partes review (IPR) of 11 patents held by Myriad Genetics will work in its favor, they generally concur that it is a quicker and less costly strategy than litigation.

This article has been updated to include a statement from Myriad Genetics.

At the San Antonio Breast Cancer Symposium last week, Myriad Genetics presented new data on its myRisk Hereditary Cancer panel, which the firm believes will help it convince physicians, patients, and payors of the advantages of multi-gene panels over single disease testing.

Industry reactions to the US Supreme Court's decision to invalidate patents on isolated gene sequences were immediate and ranged from elation to disappointment.

Women with a family history of breast and ovarian cancer who are interested in getting genetically tested to gauge whether they have a heightened risk for the diseases should speak to a genetic counselor before getting tested, patient groups are advising their members.

Pages

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.